BBA
MTNB icon

Baker Bros. Advisors’s Matinas BioPharma MTNB Stock Holding History

Baker Bros. Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,795
Closed -$1.62M – 123
2020
Q2 		$1.62M Sell
2,795
-2,211
-44% -$1.27M 0.01% 106
2020
Q1 		$2.25M Buy
5,006
+1,496
+43% +$1.35M 0.01% 88
2019
Q4 		$5.98M Buy
3,510
+863
+33% +$750K 0.03% 65
2019
Q3 		$1.25M Buy
+2,647
New +$1.43M 0.01% 95

Other funds holding MTNB

Boxer Capital
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Baker Bros. Advisors's MTNB Position: Q3 2020 in Review

Baker Bros. Advisors sold out of Matinas BioPharma (MTNB) in Q3 2020, closing a stake of 2,795 shares — an estimated $1.62M sold.

Baker Bros. Advisors first reported a position in MTNB in Q3 2019 and held it in 4 quarters. The position peaked at $5.98M in Q4 2019. 58 funds tracked by Wall St. Rank hold MTNB as of Q3 2020.

  • Baker Bros. Advisors reported no remaining Matinas BioPharma position as of Q3 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,795 Matinas BioPharma shares in Q3 2020, an estimated $1.62M.
  • Baker Bros. Advisors first reported a position in Matinas BioPharma in Q3 2019 and held it in 4 quarters.
  • Baker Bros. Advisors's Matinas BioPharma position peaked at $5.98M in Q4 2019.
  • 58 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2020.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.